Protein phosphatase-2A is down-regulated in patients within clear cell renal cell carcinoma

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 3, 2014, Pages 1147-1158

  Li, Jun ^a,b   Sheng, Chang ^a   Li, Wei ^b   Zheng, Jun Hua ^b  

^a Pudong New Area People's Hospital   (China)

^b TONGJI UNIVERSITY   (China)

Author keywords

Biomarker; Clear cell renal cell carcinoma; Phosphatase 2A; PP2A; Prognosis; Serine threonine phosphatases

Indexed keywords

PHOSPHOPROTEIN PHOSPHATASE 2; PPP2CA PROTEIN, HUMAN; TUMOR MARKER;

AGED; BIOSYNTHESIS; DOWN REGULATION; ENZYMOLOGY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

AGED; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; DOWN-REGULATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROTEIN PHOSPHATASE 2; REAL-TIME POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84899521194     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Miyamoto H, Miller JS, Fajardo DA, Lee TK, Netto GJ, Epstein JI. Non-invasive papillary urothelial neoplasms: The 2004 WHO/ISUP classification system. Pathol Int 2010; 60: 1-8.
2. Montironi R, Santinelli A, Pomante R, Mazzucchelli R, Colanzi P, Filho AL, Scarpelli M. MorTable phometric index of adult renal cell carcinoma. Virchows Archiv 2000; 437: 82-89.
3. Matsuura K, Nakada C, Mashio M, Narimatsu T, Yoshimoto T, Tanigawa M, Tsukamoto Y, Hijiya N, Takeuchi I, Nomura T, Sato F, Mimata H, Seto M, Moriyama M. Down-regulation of SAV1 plays a role in pathogenesis of high-grade clear cell renal cell carcinoma. BMC Cancer 2011; 11: 523.
4. Cindolo L, Patard JJ, Chiodini P, Schips L, Ficarra V, Tostain J, de La Taille A, Altieri V, Lobel B, Zigeuner RE, Artibani W, Guillé F, Abbou CC, Salzano L, Gallo C. Comparison of predictive accuracy of four prognostic models for non-metastatic renal cell carcinoma after nephrectomy. Cancer 2005; 104: 362-1371.
5. Karakiewicz PI, Briganti A, Chun FK, Trinh QD, Perrotte P, Ficarra V, Cindolo L, De la Taille A, Tostain J, Mulders PF, Salomon L, Zigeuner R, Prayer-Galetti T, Chautard D, Valeri A, Lechevallier E, Descotes JL, Lang H, Mejean A, Patard JJ. Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol 2007; 25: 1316-1322.
6. Jiang Z, Chu PG, Woda BA, Liu Q, Balaji KC, Rock KL, Wu CL. Combination of quantitative IMP3 and tumor stage: a new system to predict metastasis for patients with localized renal cell carcinomas. Clin Cancer Res 2008; 14: 5579-84.
7. Patil S, Ishill N, Deluca J, Motzer RJ. Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients. Cancer 2010; 116: 347-354.
8. Chen W, Wang Z, Jiang C, Ding Y. PP2A-Mediated Anticancer Therapy. Gastroenterol Res Pract 2013; 2013: 675429.
9. Wera S, Hemmings B. Serine/threonine protein phosphatases. Biochem J 1995; 311: 17-29.
10. Zhang Q, Claret FX. Phosphatases: the new brakes for cancer development? Enzyme Res 2012; 2012: 659649.
11. Inagaki N, Ito M, Nakano T, Inagaki M. Spatiotemporal distribution of protein kinase and phosphatase activities. Trends Biochem Sci 1994; 19: 448-52.
12. Janssens V, Goris J. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signaling. Biochem J 2001; 353: 417-439.
13. Virshup DM. Protein phosphatase 2A: a panoply of enzymes. Curr Opin Cell Biol 2000; 12: 180-185.
14. Westermarck J, Hahn WC. Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol Med 2008; 14: 152-160.
15. Lopez-Beltran A, Scarpelli M, Montironi R, Kirkali Z. 2004 WHO classification of the renal tumors of the adults. Eur Urol 2006; 49: 798-805.
16. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6: 655-663.
17. Lynch HT and Smyrk TC. Identifying hereditary nonpolyposis colorectal cancer. N Engl J Med 1998; 338: 1537-1538.
18. Bononi A, Agnoletto C, De Marchi E, Marchi S, Patergnani S, Bonora M, Giorgi C, Missiroli S, Poletti F, Rimessi A, Pinton P. Protein kinases and phosphatases in the control of cell fate. Enzyme Res 2011; 2011: 329098.
19. Millward TA, Zolnierowicz S, Hemmings BA. Regulation of protein kinase cascades by protein phosphatase 2A. Trends Biochem Sci 1999; 24: 186-191.
20. Sablina AA, Chen W, Arroyo JD, Corral L, Hector M, Bulmer SE, DeCaprio JA, Hahn WC. The tumor suppressor PP2A Aβ regulates the RalA GTPase. Cell 2007; 129: 969-982.
21. Mumby M. PP2A: unveiling a reluctant tumor suppressor. Cell 2007; 130: 21-24.
22. Pandey P, Seshacharyulu P, Das S, Rachagani S, Ponnusamy MP, Yan Y, Johansson SL, Datta K, Fong Lin M, Batra SK. Impaired expression of protein phosphatase 2A subunits enhances metastatic potential of human prostate cancer cells through activation of AKT pathway. Br J Cancer 2013; 108: 2590-600.